
    
      This study assesses allogeneic microbiota reconstitution (AMR) as novel treatment to improve
      symptoms and quality of life of patients with diarrhea-predominant irritable bowel syndrome
      (IBS-D).

      The investigators will perform a prospective multicenter, 2:1 randomized, double-blinded,
      placebo-controlled trial of AMR in patients with IBS-D diagnosed according to Rome III
      criteria and the IBS-QOL questionnaire.

      The experimental intervention is an infusion of donor feces via gastroscopy. The placebo
      intervention is an infusion of sterile saline via gastroscopy.

      Planned number of patients included in the study: 42 patients Planned per-protocol group: 33
      patients
    
  